U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223541) titled 'Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma' on Oct. 29.
Brief Summary: The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion of radiation therapy.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Clear Cell Renal Cell Carcinoma
Intervention:
DRUG: Cemiplimab 350 MG Intravenous Solution
Cemiplimab is a ...